Efficacy of metoprolol CR/XL on diabetic postoperative mortality and cardiovascular morbidity: a randomised, double blind, placebo-controlled, multicentre trial

Submission date
27/02/2002

Registration date
27/02/2002

Last Edited
06/09/2007

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Nutritional, Metabolic, Endocrine

[_] Prospectively registered

[_] Protocol

[_] Statistical analysis plan

[X] Results

[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Anne Benedicte Juul

Contact details
Copenhagen Trial Unit
Centre for Clinical Intervention Research
H:S Rigshospitalet
Dept 7102
Copenhagen Ø
Denmark
DK-2100
+45 3545 7156 or +45 3526 7235
Anne.j@ctu.rh.dk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
Not Applicable

Study information

Scientific Title

Acronym
DIPOM

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Diabetes mellitus and major surgery

Interventions
Diabetic patients undergoing major noncardiac surgery are randomised to 7 days of perioperative beta blocking (Metoprolol CR/XL [SeloZok®] 100 mg daily) versus placebo treatment.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Metoprolol CR/XL

Primary outcome measure
Not provided at time of registration

Secondary outcome measures
Not provided at time of registration

Overall study start date
01/07/2000

Completion date
01/07/2002

Eligibility

Key inclusion criteria
Patients 40 years of age with diabetes undergoing noncardiac major (lasting more than 1 hour) surgery

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/07/2000

Date of final enrolment
01/07/2002

Locations

Countries of recruitment
Denmark

Study participating centre
Copenhagen Trial Unit
Copenhagen Ø
Denmark
DK-2100

Sponsor information

Organisation
Copenhagen Trial Unit (Denmark)

Sponsor details
Centre for Clinical Intervention Research
H:S Rigshospitalet
Dept 7102
Copenhagen Ø
Denmark
DK-2100

Sponsor type
Research organisation

ROR
https://ror.org/05bpbnx46

Funder(s)

Funder type
Charity

Funder Name
The Danish Heart Foundation (Denmark) (ref: 01-2-5-51A-22931)

Funder Name
The Danish Diabetes Foundation (Denmark) (ref: C.1)

Funder Name
The Copenhagen Hospital Corporation's Research Council (Denmark) (ref: 109/01)

Funder Name

Programme for Strengthening Regional Collaboration within Medical Health Research (Denmark) (ref: 301-070-5199)

Funder Name

AstraZeneca (Denmark) (ref: AD-MET-0003)

Alternative Name(s)

AstraZeneca PLC, Pearl Therapeutics

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	24/06/2006		Yes	No